Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Wave Life Sciences, Inc.
Report date September 15, 2017 · Filed September 20, 2017
Jointly reported with Kagoshima Shinsangyo Sousei Investment Limited Partnership
Section 16 reporting ended · disclosed 2017-09-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 2,774,118 |
Last balance in matching sequence
After 2017-09-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-09-15 · Sale · Disposed 14,385 · Balance 2,780,480 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. F3: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. Row 2 · 2017-09-18 · Sale · Disposed 6,362 · Balance 2,774,118 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. F3: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
F3: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2017 Filed Sep 20, 2017 01:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 6,362 | $24.19 | $153,896.78 |
DisclosureSEC source: 0000899243-17-022303 · doc4.xml · nonDerivative · entry 2 Tanaka Masaharu · CIK 0001657771 · Director · 10% owner Kagoshima Shinsangyo Sousei Investment Limited Partnership · CIK 0001657769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,774,118 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. F3 · ownership.nature: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2017 Filed Sep 20, 2017 01:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 14,385 | $24.22 | $348,404.70 |
DisclosureSEC source: 0000899243-17-022303 · doc4.xml · nonDerivative · entry 1 Tanaka Masaharu · CIK 0001657771 · Director · 10% owner Kagoshima Shinsangyo Sousei Investment Limited Partnership · CIK 0001657769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,780,480 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. F3 · ownership.nature: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 19:34 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 433,825 | $24.91 | $10,806,580.75 |
DisclosureSEC source: 0000899243-17-008992 · doc4.xml · nonDerivative · entry 1 Tanaka Masaharu · CIK 0001657771 · Director · 10% owner Kagoshima Shinsangyo Sousei Investment Limited Partnership · CIK 0001657769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,794,865 F1 · price: The aggregate purchase price for the 433,825 Ordinary Shares was 1,199,998,712 Japanese yen. The purchase price per share in Column 4 of Table I was calculated based on the aggregate purchase price divided by the number of Ordinary Shares sold. The purchase price per share is shown in U.S. dollars and was converted based on the currency exchange rate as of the transaction date, March 29, 2017, rounded to the nearest whole cent. F2 · ownership.nature: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 22:46 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0000899243-16-033357 · doc4.xml · derivative · entry 1 Tanaka Masaharu · CIK 0001657771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2021-11-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on November 10, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.